이뮨온시아 자금조달 후폭풍…최대주주 유한양행 재무계획 점검 착수

Immuncell-like biotech's failed funding round (818B vs. 1.2T won) transforms technology licensing from strategic option to existential requirement, as monthly cash burn threatens liquidity reserves without product revenue in sight. The company's survival now hinges entirely on regulatory approval and licensing partnerships materializing before 2028, underscoring structural vulnerabilities of pre-revenue biotech models dependent on uncertain IP monetization.